NCT00569764

Effect on Metabolic Parameters of Abilify in SPR

The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Seoul National Hospital · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Detailed description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Conditions

• Schizophrenia
• Metabolic Syndrome

Timeline

• Start date: 2007-12-01
• Completion: 2009-10-01
• First posted: 2007-12-07
• Last updated: 2009-06-12

Locations

2 sites across 1 country: South Korea